Moderna's Advance to Phase 3

At the moment, Moderna, a biotechnology company, has advanced to the last and final phase, Phase 3. Their Phase 3 plan consists of testing their vaccine on 30,000 volunteers and put them in high risk areas of infection. The participants will be split into two groups where the first group will receive 100 micrograms of the vaccine in two doses, each a month apart. The second group will do the same but with placebo. This will be used to compare the effectiveness of the first group. They plan to begin this phase at the end of July. Moderna CEO, Stéphane Bancel, states that there is a high chance of new coronavirus vaccines to become available for distribution some time in 2021 and will most likely be seeking approval of the new vaccine later this year or early on next year.